Recovery of coronary artery distensibility after two and four years in vivo degradation of a resorbable magnesium-based scaffold
Source abstract
Abstract
The elastic properties of coronary arteries are associated with different vascular conditions, in particular the degree of severity and pathology of coronary artery disease. In contrast to permanent stents, bioresorbable scaffolds provide temporary support to the treated lesion while allowing for restoration of the physiological vasomotion due to resorption within a certain period of time. Coronary artery distensibility may serve as a measure for vascular restoration after implantation and in vivo degradation of a bioresorbable scaffold. This study presents an investigation of the distensibility of porcine coronary arteries two and four years after implantation of a resorbable magnesium-based scaffold (RMS, Freesolve TM scaffold prototype and Freesolve TM scaffold, respectively, Teleflex) based on measurements of the pressure-dependent luminal area using an ex vivo test setup including intravascular optical coherence tomography. In case of a normotensive pressure regime, mean distensibility values were found to be 1.45 ± 0.47 × 10 -3 mmHg -1 for the untreated artery regions and 1.03 × 10 -3 mmHg -1 for the RMS region after two years in vivo degradation (71% distensibility recovery) as well as 1.40 ± 0.01 × 10 -3 mmHg -1 after four years in vivo degradation (97% distensibility recovery), respectively. Reference measurements of a permanent drug eluting stent region revealed a distensibility of 0.80 × 10 -3 mmHg -1 . The findings of this study support the hypothesis that the radial elastic properties of the coronary artery can be regained following the in vivo degradation of a magnesium-based scaffold. Statement of significance The elastic properties of coronary arteries are associated with the pathology of coronary artery disease. Measurement of coronary artery distensibility can be used to quantitatively assess passive radial elasticity of the arterial wall. Within the current study, two porcine hearts two years and four years after implantation of a resorbable magnesium-based scaffold were investigated regarding their coronary artery distensibility. Using an ex vivo test setup based on intravascular optical coherence tomography overcomes many limitations of in vivo investigations. The results show an increasing distensibility recovery over degradation time. For the first time, the hypothesis that the elastic properties of the coronary arteries can be restored following the in vivo degradation of a magnesium-based scaffold could be verified by quantitative measurements of distensibility
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: Coronary Interventions and Diagnostics · Elasticity and Material Modeling · Ultrasound Imaging and Elastography
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (68)
Show source-provided references
1. Safety and performance of the DRug-Eluting Absorbable Metal Scaffold (DREAMS) in patients with de novo coronary lesions: 3-year results of the prospective, multicentre, first-in-man BIOSOLVE-I trial10.4244/EIJ-D-15-00371 ↗
2. From metallic cages to transient bioresorbable scaffolds: change in paradigm of coronary revascularization in the upcoming decade?10.1093/eurheartj/ehr384 ↗
3. 24-Month clinical follow-up and mechanistic insights from intravascular imaging following coronary implantation of the novel DynamX bioadaptor platform10.1016/j.carrev.2022.09.009 ↗
4. Final 36-month outcomes from the Multicenter DynamX study evaluating a novel thin-strut Novolimus-eluting coronary bioadaptor system and supporting preclinical data10.31083/j.rcm2408221 ↗
5. Update on coronary artery bioresorbable vascular scaffolds in percutaneous coronary revascularization10.31083/j.rcm.2021.01.225 ↗
6. Evaluation of the second generation of a bioresorbable everolimus-eluting vascular scaffold for the treatment of de novo coronary artery stenosis: 12-month clinical and imaging outcomes10.1016/j.jacc.2011.05.050 ↗
7. Comparison of an everolimus-eluting bioresorbable scaffold with an everolimus-eluting metallic stent for the treatment of coronary artery stenosis (ABSORB II): a 3 year, randomised, controlled, single-blind, multicentre clinical trial10.1016/S0140-6736(16)32050-5 ↗
8. 3-Year clinical outcomes with Everolimus-eluting bioresorbable coronary scaffolds: the ABSORB III trial10.1016/j.jacc.2017.10.010 ↗
9. Safety and clinical performance of the drug-eluting absorbable metal scaffold in the treatment of subjects with de novo lesions in native coronary arteries at 36-month follow-up: BIOSOLVE-II and BIOSOLVE-III: abstract TCT-18810.1016/j.jacc.2019.08.247 ↗
10. Sustained safety and clinical performance of a drug-eluting absorbable metal scaffold up to 24 months: pooled outcomes of BIOSOLVE-II and BIOSOLVE-III10.4244/EIJ-D-17-00254 ↗
11. Safety and efficacy of the resorbable magnesium scaffold, magmaris in a real-world setting - 24-month follow-up of the full cohort (2066 subjects) of the BIOSOLVE-IV Registry: presented at TCT, September 2022, Boston USA. Clinical trials.Giv: NCT02817802
12. One- and two-year clinical outcomes of treatment with resorbable magnesium scaffolds for coronary artery disease: the prospective, international, multicentre BIOSOLVE-IV registry
13. G. Starmer, 36-Month outcomes of the BIOSOLVE-IV Registry: safety and efficacy of the resorbable magnesium scaffold magmaris in a real-world setting, San Francisco, CA, 2024.10.1016/j.jacc.2023.09.086 ↗
14. Comparison of acute thrombogenicity for metallic and polymeric bioabsorbable scaffolds: magmaris versus absorb in a porcine arteriovenous shunt model10.1161/CIRCINTERVENTIONS.116.004762 ↗
15. Outcomes of the two generations of bioresorbable scaffolds (Magmaris vs. Absorb) in acute coronary syndrome in routine clinical practice
16. Two-year outcomes for patients with non-ST-elevation acute coronary syndrome treated with magmaris and absorb bioresorbable scaffolds in large-vessel lesions10.3390/jpm14050540 ↗
17. Sustained safety and efficacy of the magnesium scaffold: does the Magmaris scaffold call for the return of BRS research… and randomised controlled trials?10.4244/EIJV15I15A238 ↗
18. Safety and performance of the third-generation drug-eluting resorbable coronary magnesium scaffold system in the treatment of subjects with de novo coronary artery lesions: 6-month results of the prospective, multicenter BIOMAG-I first-in-human study10.1016/j.eclinm.2023.101940 ↗
19. ClinicalTrials.gov, Safety and clinical performance of the DREAMS 3G resorbable magnesium scaffold system (BIOMAG-II), 2025. https://clinicaltrials.gov/study/NCT05540223?cond=BIOMAG&rank=2 (accessed 29 August 2025).
20. A new resorbable magnesium scaffold for de novo coronary lesions (DREAMS 3): one-year results of the BIOMAG-1 first-in-human study10.4244/EIJ-D-23-00326 ↗
21. BIOMAG-I: two-year clinical outcomes of the resorbable magnesium scaffold - DREAMS 3G
22. Degradation of a novel magnesium alloy-based bioresorbable coronary scaffold in a swine coronary artery model10.1007/s12928-024-01023-3 ↗
23. In vivo serial invasive imaging of the second-generation drug-eluting absorbable metal scaffold (Magmaris - DREAMS 2G) in de novo coronary lesions: insights from the BIOSOLVE-II first-In-man trial10.1016/j.ijcard.2017.12.053 ↗
24. Magnesium-based resorbable scaffold versus permanent metallic sirolimus-eluting stent in patients with ST-segment elevation myocardial infarction: the MAGSTEMI randomized clinical trial10.1161/CIRCULATIONAHA.119.043467 ↗
25. A new resorbable magnesium scaffold for de novo coronary lesions (DREAMS 3G): 12-month results of the BIOMAG-I fist-in-human study
26. Determinants of coronary compliance in patients with coronary artery disease: an intravascular ultrasound study10.1016/0735-1097(94)90632-7 ↗
27. Assessment of coronary artery distensibility by intravascular ultrasound. Application of simultaneous measurements of luminal area and pressure10.1161/01.CIR.91.12.2904 ↗
28. Coronary compliance in patients following orthotopic heart transplantationAn intravascular ultrasound study10.1093/oxfordjournals.eurheartj.a014808 ↗
29. Pulsatile diameter change of coronary artery lumen estimated by intravascular ultrasound
30. Coronary artery distensibility in diabetic patients with simultaneous measurements of luminal area and intracoronary pressure: evidence of impaired reactivity to nitroglycerin10.1016/S0735-1097(99)00331-9 ↗
31. Coronary artery compliance and adaptive vessel remodelling in patients with stable and unstable coronary artery disease10.1136/heart.84.3.314 ↗
32. Coronary artery distensibility and compensatory vessel enlargement – a novel parameter influencing vascular remodeling?10.1007/s003950170033 ↗
33. Determinants of coronary artery compliance in subjects with and without angiographic coronary artery disease10.1016/S0735-1097(02)01842-9 ↗
34. Endothelin-A receptor antagonism promotes decreased vasodilatation but has no differential effect on coronary artery compliance10.1097/01.fjc.0000166209.19921.fc ↗
35. Effect of stent implantation on upstream coronary artery compliance–a cause of late plaque rupture?10.1016/j.amjcard.2005.04.042 ↗
36. Compliance mismatch between stenotic and distal reference segment is associated with coronary artery disease instability10.1016/j.atherosclerosis.2009.02.025 ↗
37. Coronary artery distensibility assessed by 3.0 tesla Coronary magnetic resonance imaging in subjects with and without Coronary artery disease10.1016/j.amjcard.2011.03.078 ↗
38. Longitudinal heterogeneity of coronary artery distensibility in plaques related to acute coronary syndrome10.1007/s00392-012-0424-6 ↗
39. Impaired coronary artery distensibility is an endothelium-dependent process and is associated with vulnerable plaque composition10.1111/cpf.12220 ↗
40. The relationship between coronary artery distensibility and fractional flow reserve10.1371/journal.pone.0181824 ↗
41. Mechanism of drug-eluting absorbable metal scaffold restenosis: a serial optical coherence tomography study10.1161/CIRCINTERVENTIONS.119.008657 ↗
42. Optical coherence tomography in coronary atherosclerosis assessment and intervention10.1038/s41569-022-00687-9 ↗
43. A review of the Ultrathin Orsiro biodegradable polymer drug-eluting stent in the treatment of coronary artery disease10.17925/HI.2019.13.2.17 ↗
44. Preclinical evaluation of the degradation kinetics of third-generation resorbable magnesium scaffolds10.4244/EIJ-D-22-00718 ↗
45. Preclinical evaluation of degradation kinetics and elemental mapping of first- and second-generation bioresorbable magnesium scaffolds10.4244/EIJ-D-17-00708 ↗
46. Ultrathin Bioresorbable polymer sirolimus-eluting stents versus durable polymer everolimus-eluting stents: BIOFLOW V final 5-year outcomes10.1016/j.jcin.2022.07.027 ↗
47. The Orsiro Ultrathin, bioresorbable-polymer Sirolimus-eluting stent: a review of current evidence10.1016/j.carrev.2019.12.039 ↗
48. Bioresorbable drug-eluting magnesium-alloy scaffold: design and feasibility in a porcine coronary model10.4244/EIJV8I12A218 ↗
49. A method to determine the radial compliance of porcine coronary arteries ex vivo via optical coherence tomography10.1515/cdbme-2020-3013 ↗
50. The evolution of coronary stents: a brief review
51. Evaluation of measurement data — Guide to the expression of uncertainty in measurement, Joint Committee for Guides in Metrology
52. Relation between age and carotid artery intima-medial thickness: a systematic review10.1002/clc.22934 ↗
53. Understanding and managing in-stent restenosis: a review of clinical data, from pathogenesis to treatment10.21037/jtd.2016.10.93 ↗
54. Second-generation magnesium scaffold Magmaris: device design and preclinical evaluation in a porcine coronary artery model10.4244/EIJ-D-16-00915 ↗
55. Intracoronary stenting and angiographic results: strut thickness effect on restenosis outcome (ISAR-STEREO) trial10.1161/01.CIR.103.23.2816 ↗
56. Intracoronary stenting and angiographic results: strut thickness effect on restenosis outcome (ISAR-STEREO-2) trial10.1016/S0735-1097(03)00119-0 ↗
57. Sustained safety and performance of the second-generation drug-eluting absorbable metal scaffold in patients with de novo coronary lesions: 12-month clinical results and angiographic findings of the BIOSOLVE-II first-in-man trial10.1093/eurheartj/ehw196 ↗
58. Drug-eluting stent safety: findings from preclinical studies10.1586/14779072.6.10.1379 ↗
59. Safety and performance of the second-generation drug-eluting absorbable metal scaffold in patients with de-novo coronary artery lesions (BIOSOLVE-II): 6 month results of a prospective, multicentre, non-randomised, first-in-man trial10.1016/S0140-6736(15)00447-X ↗
60. Optical coherence tomography characterization of degradation kinetics between second- and third-generation resorbable magnesium scaffold
61. Vascular response following implantation of the third-generation drug-eluting resorbable coronary magnesium scaffold: an intravascular imaging analysis of the BIOMAG-I first-in-human study10.4244/EIJ-D-24-00055 ↗
62. Measurement of coronary artery compliance and stiffness index with novel application of optical coherence tomography in re-pressurised cadaveric coronary arteries10.1093/eurheartj/ehx502.P2357 ↗
63. Temporal changes in coronary plaque as assessed by an artificial intelligence-based optical coherence tomography: from the first-in-human trial on DREAMS 3G scaffold10.1093/ehjci/jead299 ↗
64. Mechanical behavior of in vivo degraded second generation resorbable magnesium scaffolds (RMS)10.1016/j.jmbbm.2018.12.008 ↗
65. Radial compliance of porcine coronary arteries ex vivo under pulsatile flow – perspectives for stent biomechanics10.1515/cdbme-2022-1125 ↗
66. The properties of blood vessels
67. Implantation of paclitaxel-eluting stent impairs the vascular compliance of arteries in porcine coronary stenting model10.1016/j.atherosclerosis.2008.04.039 ↗
68. Contrast-free optical coherence tomography:systematic evaluation of non-contrast media for intravascular assessment10.1371/journal.pone.0237588 ↗